MP Biomedicals completes its range of in vitro diagnostic tests for infectious diseases with new immunochromatographic-based qualitative rapid tests.The new diagnostic kits by MP Biomedicals leverage cutting-edge technology to deliver precise results, enabling healthcare professionals a rapid and accurate detection of Helicobacter pylori, Salmonella typhi and Vibrio cholerae serogroups O1 and O139.
CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes